Skip to content
Demo
‹ Back to IndustriesSciences

SpaceX targets a Falcon Heavy launch Tuesday

SpaceX prepared to launch the Falcon Heavy rocket, designed to be the most powerful rocket since Apollo's Saturn 5 and the first without government funding. The launch was scheduled for 1:30 PM Eastern on Tuesday with a Wednesday backup, viewable via SpaceX's website and YouTube.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

Promoted content from Spacex on MarketScale.

By Sciences · · SpacexFalcon HeavySpace ExplorationRocket Launch
Share
SpaceX targets a Falcon Heavy launch Tuesday

Key takeaways

01

SpaceX hopes to launch its Falcon Heavy rocket this Tuesday, defying skeptics and correcting past failures.

02

If successful, the Falcon Heavy would be the world’s most powerful rocket and a huge step for the company.

03

Viewable on the SpaceX website and YouTube, the launch aims to go off at 1:30 PM Eastern, with a backup…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

SpaceX hopes to launch its Falcon Heavy rocket this Tuesday, defying skeptics and correcting past failures. If successful, the Falcon Heavy would be the world’s most powerful rocket and a huge step for the company. Viewable on the SpaceX website and YouTube, the launch aims to go off at 1:30 PM Eastern, with a backup launch on Wednesday if weather is poor.

The Falcon Heavy will be the most powerful rocket launched since Apollo’s Saturn 5 and the first without government aid. Founder Elon Musk aims to colonize Mars in the near future and Falcon Heavy is no small part of that vision. Given the opportunity, would you become a Martian?

Spacex

Part of this channel

Spacex

Designing Rockets and Spacecraft for a Multiplanetary Future

Visit the channel

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Book a Demo →Talk to Sales

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

Book a Demo →Try it Free

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Why ISPE put peptide and oligo facility design in one guide

Why ISPE put peptide and oligo facility design in one guide

ISPE's new Baseline Guide covers oligonucleotide and peptide facility design in one document, says Jim Love of CRB. It pairs a GMP survey of existing plants with a sustainability outlook and a piping safety framework for scale-up, while FDA's oligonucleotide guidances under dockets opened in 2022 and 2024 remain the regulator's own reference.

  • 01Peptide plants inherited API chemistry thinking and oligo plants biotech thinking; ISPE’s guide puts both modalities in one facility document with both inheritances.
  • 02The guide has three parts: a GMP survey of existing oligo and peptide plants, a forecast of how sustainability and scale will change the processes, and a safety framework for connective piping and equipment.
  • 03FDA keeps its own oligonucleotide-specific guidances under dockets opened in 2022 and 2024, so the ISPE guide works as an industry consensus alongside regulation rather than in place of it.

Nov 5, 2026

Collagen builder Astrion outdrew AstraGin at NuLiv's Bangkok booth

Collagen builder Astrion outdrew AstraGin at NuLiv's Bangkok booth

NuLiv Science says Astrion, its collagen-building ingredient, drew more interest than AstraGin at Vitafoods Asia 2026 in Bangkok, held September 2 to 4. Brands also asked for probiotic strains for pet weight loss, children, and women's health. New trials for AstraGin in Nutrients and Senactiv provide updated evidence for these distinct ingredients.

  • 01At Vitafoods Asia 2026 in Bangkok, Astrion drew more booth interest than AstraGin, NuLiv’s absorption flagship.
  • 02NuLiv says probiotic requests are now split by pet, child and life stage, and the show preview lists strains for women’s health, emotional wellbeing and the gut-muscle axis.
  • 03A newly published crossover trial in Nutrients found AstraGin raised branched-chain amino acid absorption and grip strength in adults aged 60 to 80.

Nov 5, 2026

Astrion drew more interest than AstraGin at NuLiv Science's Bangkok booth

Astrion drew more interest than AstraGin at NuLiv Science's Bangkok booth

NuLiv Science reported from Vitafoods Asia 2026 in Bangkok that collagen-building Astrion drew more interest than AstraGin, its absorption ingredient, as collagen and anti-aging products are heavily marketed and sold in almost every store, a company representative said. A 150-person trial published in Cosmetics in June 2025 found oral Astrion raised skin collagen 13.2%. Mordor Intelligence still puts North America at 37.95% of collagen supplement revenue, with Asia-Pacific growing fastest at 11.65%.

  • 01NuLiv Science expected AstraGin to lead in a new market; at Vitafoods Asia 2026 in Bangkok, its collagen-boosting Astrion drew more attention, the company said.
  • 02Oral Astrion raised skin collagen content 13.2% over 12 weeks in a 150-person, placebo-controlled trial published in Cosmetics in June 2025.
  • 03North America held 37.95% of collagen supplement revenue in 2025 while Asia-Pacific grows fastest at 11.65% a year, Mordor Intelligence estimates.

Nov 5, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For Sciences teams

See how Sciences teams use MarketScale →

Executive Thought Leadership

Explore Channels

Industry news, analysis, and expert perspectives

Professional AV›Engineering & Construction›Education Technology›Healthcare›Energy›Software & Technology›Retail›Business Services›Industrial IoT›Sports & Entertainment›Transportation›Sciences›Building Management›Food & Beverage›Architecture & Design›Hospitality›Marketing Tech›
Keep exploring

More from Sciences

Sciences hubMore expert Sciences coverage.Explore →Executive Thought LeadershipPut researchers on the record.Explore →FinThriveComplex topics, made clear.Explore →State of GEO & AI VisibilityHow B2B brands get cited by AI search.Explore →

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512